Source:http://linkedlifedata.com/resource/pubmed/id/18559720
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2008-7-24
|
| pubmed:abstractText |
In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN). There were 4007 patients with Hx-HTN (eplerenone: n=1983) and 2625 patients without Hx-HTN (eplerenone: n=1336). Propensity scores for eplerenone use, separately calculated for patients with and without Hx-HTN, were used to assemble matched cohorts of 1838 and 1176 pairs of patients. In patients with Hx-HTN, all-cause mortality occurred in 18% of patients treated with placebo (rate, 1430/10 000 person-years) and 14% of patients treated with eplerenone (rate, 1058/10 000 person-years) during 2350 and 2457 years of follow-up, respectively (hazard ratio [HR]: 0.71; 95% CI: 0.59 to 0.85; P<0.0001). Composite end point of cardiovascular hospitalization or cardiovascular mortality occurred in 33% of placebo-treated patients (3029/10 000 person-years) and 28% of eplerenone-treated patients (2438/10 000 person-years) with Hx-HTN (HR: 0.82; 95% CI: 0.72 to 0.94; P=0.003). In patients without Hx-HTN, eplerenone reduced heart failure hospitalization (HR: 73; 95% CI: 0.55 to 0.97; P=0.028) but had no effect on mortality (HR: 0.91; 95% CI: 0.72 to 1.15; P=0.435) or on the composite end point (HR: 0.91; 95% CI: 0.76 to 1.10; P=0.331). Eplerenone should, therefore, be prescribed to all of the post-acute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure regardless of Hx-HTN.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1524-4563
|
| pubmed:author |
pubmed-author:AliAhmedA,
pubmed-author:AschermannMichaelM,
pubmed-author:CardosoJosé SJS,
pubmed-author:CorbalánRamonR,
pubmed-author:KrumHenryH,
pubmed-author:LoveThomas ETE,
pubmed-author:NicolauJoseJ,
pubmed-author:ParkhomenkoAlexanderA,
pubmed-author:PittBertramB,
pubmed-author:ShiHarryH,
pubmed-author:SolomonHenryH,
pubmed-author:ZannadFaiezF
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
52
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
271-8
|
| pubmed:dateRevised |
2010-8-20
|
| pubmed:meshHeading |
pubmed-meshheading:18559720-Aged,
pubmed-meshheading:18559720-Aldosterone Antagonists,
pubmed-meshheading:18559720-Cause of Death,
pubmed-meshheading:18559720-Dose-Response Relationship, Drug,
pubmed-meshheading:18559720-Double-Blind Method,
pubmed-meshheading:18559720-Drug Administration Schedule,
pubmed-meshheading:18559720-Female,
pubmed-meshheading:18559720-Heart Failure,
pubmed-meshheading:18559720-Humans,
pubmed-meshheading:18559720-Hypertension,
pubmed-meshheading:18559720-Logistic Models,
pubmed-meshheading:18559720-Male,
pubmed-meshheading:18559720-Middle Aged,
pubmed-meshheading:18559720-Multivariate Analysis,
pubmed-meshheading:18559720-Myocardial Infarction,
pubmed-meshheading:18559720-Probability,
pubmed-meshheading:18559720-Prognosis,
pubmed-meshheading:18559720-Risk Assessment,
pubmed-meshheading:18559720-Spironolactone,
pubmed-meshheading:18559720-Survival Analysis,
pubmed-meshheading:18559720-Treatment Outcome
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
|
| pubmed:affiliation |
University of Michigan, 1500 E Medical Center Dr, 3910 Taubman Center, Ann Arbor, MI 48109-0366, USA. bpitt@med.umich.edu
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|